Luminex (LMNX) 10-K 26 Feb 21 2020 FY Annual report Financial data

COVER PAGE Document

COVER PAGE Document - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 26, 2021	Jun. 30, 2020
COVER PAGE [Abstract]
Entity Central Index Key	0001033905
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
City Area Code	(512)
Entity Address, Address Line One	12212 Technology Blvd.,
Entity Incorporation, State or Country Code	DE
Document Type	10-K
Entity File Number	000-30109
Entity Tax Identification Number	74-2747608
Entity Address, City or Town	Austin,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78727
Local Phone Number	219-8020
Trading Symbol	LMNX
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Registrant Name	LUMINEX CORPORATION
Entity Common Stock, Shares Outstanding		46,688,309
Amendment Flag	false
Entity Public Float			$ 1,344,295,984
Adjustments to Additional Paid in Capital, Warrant Issued	$ 19,968,000

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 309,407	$ 59,173
Accounts Receivable, Net, Current	66,963	55,815
Inventory, Net	123,134	77,084
Other	9,527	10,398
Total current assets	509,031	202,470
Property, Plant and Equipment, Net	64,146	65,515
Intangible Assets, Net (Excluding Goodwill)	78,796	90,336
Goodwill	118,145	118,145
Operating Lease, Right-of-Use Asset	17,768	20,439
Deferred Income Tax Assets, Net	21,077	27,702
Other Assets, Noncurrent	16,500	19,122
Total assets	825,463	543,729
Current liabilities:
Accounts payable	21,049	17,983
Accrued Liabilities, Current	56,365	31,872
Short-term unearned revenue	10,047	8,214
Total current liabilities	87,461	58,069
Long-term unearned revenue	1,658	1,633
Operating Lease, Liability, Noncurrent	13,366	17,182
Other long-term liabilities	2,131	1,985
Total liabilities	307,752	78,869
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock, Value, Outstanding	45	44
Preferred Stock, Value, Outstanding	0	0
Additional Paid in Capital	434,021	380,304
Accumulated Other Comprehensive Income (Loss), Net of Tax	(142)	(1,380)
Retained earnings	83,787	85,892
Stockholders' Equity Attributable to Parent	517,711	464,860
Liabilities and Equity	825,463	543,729
Long-term Debt	$ 203,136	$ 0

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	45,682,687	44,325,369
Common Stock, Shares, Outstanding	45,682,687	44,325,369
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Accounts receivable, allowance for doubtful accounts	$ 1,140	$ 843
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 117,467	$ 99,849

INCOME STATEMENTS

INCOME STATEMENTS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues	$ 111,393	$ 106,060	$ 109,519	$ 90,424	$ 90,501	$ 78,673	$ 83,056	$ 82,408	$ 417,396	$ 334,638	$ 315,818
Cost of Goods and Services Sold	46,949	42,679	39,838	40,078	40,636	36,833	37,829	36,601	169,544	151,899	120,327
Gross margin	64,444	63,381	69,681	50,346	49,865	41,840	45,227	45,807	247,852	182,739	195,491
Research and development									53,651	56,228	47,164
Selling, General and Administrative Expense									140,216	127,183	111,816
Amortization of Intangible Assets									11,542	11,407	8,665
Operating Expenses	53,944	51,855	50,905	48,705	46,882	47,562	50,983	49,391	205,409	194,818	167,645
Operating income	10,500	11,526	18,776	1,641	2,983	(5,722)	(5,756)	(3,584)	42,443	(12,079)	27,846
Other income, net									(11,912)	3,100	465
Income (Loss) from Equity Method Investments									(1,591)	(523)	0
Income (Loss) Attributable to Parent, before Tax									28,940	(9,502)	28,311
Provision for income taxes									(13,770)	5,664	(9,803)
Net Income (Loss) Attributable to Parent	$ 239	$ 1,767	$ 12,510	$ 654	$ 3,383	$ (5,250)	$ (4,931)	$ 2,960	15,170	(3,838)	18,508
Net Income (Loss) Available to Common Stockholders, Basic									14,873	(3,773)	18,196
Net Income (Loss) Available to Common Stockholders, Diluted									$ 14,872	$ (3,775)	$ 18,197
Earnings Per Share [Abstract]
Earnings Per Share, Basic	$ 0.01	$ 0.04	$ 0.27	$ 0.01	$ 0.08	$ (0.12)	$ (0.11)	$ 0.07	$ 0.33	$ (0.09)	$ 0.42
Earnings Per Share, Diluted	0.01	0.04	0.27	0.01	0.07	(0.12)	(0.11)	0.07	$ 0.32	$ (0.09)	$ 0.41
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted Average Number of Shares Outstanding, Basic									45,102	44,148	43,727
Weighted Average Number of Shares Outstanding, Diluted									45,820	44,148	44,291
Common Stock, Dividends, Per Share, Declared	$ 0.10	$ 0.09	$ 0.09	$ 0.09	$ 0.09	$ 0.09	$ 0.06	$ 0.06	$ 0.37	$ 0.30	$ 0.24
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax									$ 1,238	$ (253)	$ (502)
Other Comprehensive Income (Loss), Net of Tax									1,238	(253)	(502)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent									$ 16,408	$ (4,091)	$ 18,006

INCOME STATEMENTS INCOME STATEM

INCOME STATEMENTS INCOME STATEMENTS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Operating Expenses	$ 53,944	$ 51,855	$ 50,905	$ 48,705	$ 46,882	$ 47,562	$ 50,983	$ 49,391	$ 205,409	$ 194,818	$ 167,645
Operating Income (Loss)	$ 10,500	$ 11,526	$ 18,776	$ 1,641	$ 2,983	$ (5,722)	$ (5,756)	$ (3,584)	$ 42,443	$ (12,079)	$ 27,846

CASH FLOWS STATEMENTS

CASH FLOWS STATEMENTS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net Income (Loss) Attributable to Parent	$ 15,170	$ (3,838)	$ 18,508
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation, Depletion and Amortization	30,483	28,529	23,674
Stock-based compensation expense	14,852	13,198	12,226
Increase (Decrease) in Deferred Income Taxes	6,593	(7,444)	8,159
Gain (Loss) on Disposition of Property Plant Equipment	851	641	730
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions	1,592	(2,719)	0
Other Operating Activities, Cash Flow Statement	2,086	(329)	(1,369)
Changes in operating assets and liabilities:
Accounts receivable	(11,139)	(2,440)	(1,569)
Inventories	(45,973)	(13,559)	(6,827)
Operating Assets	4,125	4,789	(3,319)
Operating Liabilities	19,686	(5,630)	103
Accounts payable	3,184	3,370	4
Unearned revenue	1,888	(1,031)	579
Net cash from operations	49,931	13,537	50,899
Net Cash Provided by (Used in) Financing Activities [Abstract]
Common stock issued	20,435	3,750	4,570
Payments Related to Tax Withholding for Share-based Compensation	(2,373)	(2,095)	(2,312)
Common stock cash dividends paid	(16,485)	(12,153)	(10,654)
Net cash used in financing	219,166	(10,498)	(8,396)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Additions to property and equipment	(17,910)	(16,249)	(21,292)
Payments to Acquire Businesses, Net of Cash Acquired	0	0	(65,381)
Payments for (Proceeds from) Previous Acquisition	0	1,916	0
Payments to Acquire Notes Receivable	0	0	(1,000)
Payments to Acquire Equity Method Investments	0	6,980	0
Proceeds from (Payments to) Noncontrolling Interests	0	734	(1,782)
Proceeds from Sale of Productive Assets	0	0	2
Payments to Acquire Intangible Assets	22	(40)	(4,000)
Net cash used in investing	(17,888)	(20,619)	(93,453)
Effect of foreign exchange rates on cash and cash equivalents	(975)	312	279
Net change in cash and cash equivalents	250,234	(17,268)	(50,671)
Cash and cash equivalents, end of period	309,407	59,173	76,441
Amortization of Debt Issuance Costs	6,533
Proceeds from Convertible Debt	252,247	0	0
Payments for Hedge, Financing Activities	(54,626)	0	0
Proceeds from Issuance of Warrants	$ 19,968	$ 0	$ 0

STOCKHOLDERS' EQUITY STATEMENTS

STOCKHOLDERS' EQUITY STATEMENTS - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated other comprehensive Income (loss)	Retained earnings
Stockholders' Equity Attributable to Parent	$ 437,907	$ 43	$ 350,834	$ (625)	$ 87,655
Common Stock, Shares, Outstanding	43,404,493
Stock Issued During Period, Value, Stock Options Exercised	$ 2,814	$ 0	2,814	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		253,152
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(2,311)	$ 1	(2,312)	0	0
Stock-based compensation expense	$ 12,187	$ 0	12,187	0	0
Stock Issued During Period, Shares, Employee Stock Purchase Plans	518,111	83,811
ESPP	$ 1,740	$ 0	1,740	0	0
Net Income (Loss) Attributable to Parent	18,508	0	0	0	18,508
Common stock cash dividends	(10,710)	0	86	0	(10,796)
Other, net	(8,023)	$ 0	0	0	(8,023)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		157,754
Stockholders' Equity Attributable to Parent	467,656	$ 44	365,349	(1,127)	103,390
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (502)	0	0	(502)	0
Common Stock, Shares, Outstanding	43,899,210
Stock Issued During Period, Value, Stock Options Exercised	$ 1,698	$ 0	1,698	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		217,620
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(2,095)	$ 0	(2,095)	0	0
Stock-based compensation expense	$ 13,198	$ 0	13,198	0	0
Stock Issued During Period, Shares, Employee Stock Purchase Plans	631,553	113,442
ESPP	$ 2,030	$ 0	2,030	0	0
Net Income (Loss) Attributable to Parent	(3,838)	0	0	0	(3,838)
Common stock cash dividends	(13,536)	$ 0	124	0	(13,660)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		95,097
Stockholders' Equity Attributable to Parent	464,860	$ 44	380,304	(1,380)	85,892
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (253)	0	0	(253)	0
Common Stock, Shares, Outstanding	44,325,369
Stock Issued During Period, Value, Stock Options Exercised	$ 17,989	$ 1	17,988	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		240,100
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(2,373)	$ 0	(2,373)	0	0
Stock-based compensation expense	$ 14,852	$ 0	14,852	0	0
Stock Issued During Period, Shares, Employee Stock Purchase Plans	758,700	127,147
ESPP	$ 2,391	$ 0	2,391	0	0
Net Income (Loss) Attributable to Parent	15,170	0	0	0	15,170
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt	41,950		41,950
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments	(41,243)		(41,243)
Adjustments to Additional Paid in Capital, Warrant Issued	19,968		19,968
Common stock cash dividends	(17,091)	$ 0	184	0	(17,275)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		990,071
Stockholders' Equity Attributable to Parent	517,711	$ 45	434,021	(142)	83,787
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ 1,238	$ 0	$ 0	$ 1,238	$ 0
Common Stock, Shares, Outstanding	45,682,687

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Comprehensive Income (Loss) Note [Text Block]	NOTE 8 — OTHER COMPREHENSIVE (LOSS) INCOME Comprehensive loss represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by and distributions to shareholders. Other comprehensive loss for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments. The following table presents the changes in each component of accumulated other comprehensive loss, net of tax (in thousands): Accumulated Other Comprehensive Loss Items - Foreign Currency Balance as of December 31, 2019 $ (1,380) Other comprehensive loss 1,238 Net current-period other comprehensive loss 1,238 Balance as of December 31, 2020 $ (142) There are no tax benefits or expenses related to the other comprehensive loss for the twelve months ended December 31, 2020.

INVESTMENTS Details (Details)

INVESTMENTS Details (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Document Period End Date	Dec. 31, 2020
Other Long-term Investments	$ 9,909	$ 11,501
Prepaid Expense and Other Assets, Noncurrent	1,137	1,594
Other Assets, Noncurrent	16,500	19,122
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 5,454	$ 6,027

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME Details (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (142)	$ (1,380)
Other Comprehensive Income (Loss), Net of Tax	$ 1,238	$ (253)	$ (502)

Investments, Equity Method and

Investments, Equity Method and Joint Ventures	12 Months Ended
	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure	Non-Marketable Securities and Other-Than-Temporary Impairment During the year ended December 31, 2018, the Company made a $1.8 million investment in Combinati, a private company. Subsequently, on October 1, 2019, the Company made an additional $7.0 million investment in Combinati, bringing the Company's ownership to approximately 28.4% of the voting interest of Combinati. The Company does not have majority control of the entity in which the investment was made, but has the ability to exercise significant influence over operating and financial policies due to its larger ownership percentage and its seat on the Board of Directors. The Company does not have unilateral decision making power, and therefore will not consolidate the investee; therefore, the Company accounts for this investment using the equity method. In the fourth quarter of 2019, we remeasured the existing, minority interest investment based on the fair value prior to the additional investment and recorded a gain of approximately $3.2 million in Other income, net in the Consolidated Statements of Comprehensive Income. The minority interest investment in Combinati is classified in equity method investments to distinguish it from other minority interest investments that take the fair value alternative. The Company's proportionate share of income or loss of approximately 28.4% is recorded in other income (expense), net in the Consolidated Statement of Comprehensive Income. This non-marketable equity investment is recorded at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. The Company periodically reviews this equity investment for other-than-temporary declines in fair value based on the specific identification method and writes down the investment to its fair value when it determines that an other-than-temporary decline has occurred. As of December 31, 2020, the carrying value of the Company’s total investment in Combinati was $9.9 million, which exceeded the Company’s share of Combinati’s net assets by $8.1 million and is not amortized. For the year ended December 31, 2020, the Company recorded the allocable share of Combinati’s net income in its Consolidated Statement of Compre hensive Income and as an adjustment to the invested balance.

ACCOUNTS RECEIVABLE (Notes)

ACCOUNTS RECEIVABLE (Notes)	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	NOTE 3 — ACCOUNTS RECEIVABLE AND RESERVES Accounts receivable consisted of the following (in thousands): 2020 2019 Accounts receivable $ 68,629 $ 56,956 Less: Allowance for doubtful accounts (1,666) (1,141) $ 66,963 $ 55,815 The following table summarizes the changes in the allowance for doubtful accounts (in thousands): Balance at December 31, 2017 $ 1,345 Net increases charged to costs and expenses (437) Write-offs of uncollectible accounts (65) Balance at December 31, 2018 $ 843 Net recoveries charged to costs and expenses 400 Write-offs of uncollectible accounts (102) Balance at December 31, 2019 1,141 Net recoveries charged to costs and expenses 546 Write-offs of uncollectible accounts (21) Balance at December 31, 2020 1,666

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4 — INVENTORIES, NET Inventories consisted of the following at December 31 (in thousands): 2020 2019 Parts and supplies $ 86,380 $ 45,459 Work-in-progress 18,858 15,532 Finished goods 17,896 16,093 $ 123,134 $ 77,084 T he Company has non-cancellable purchase commitments with certain of its component suppliers in the amount of approximately $68.1 million at December 31, 2020. Should production requirements fall below the level of the Company’s commitments, the Company coul d be required to take delivery of inventory for which it has no immediate need or incur an increased cost per unit going forward.

FAIR VALUE (Notes)

FAIR VALUE (Notes)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 5 — FAIR VALUE MEASUREMENT ASC 820 “Fair Value Measurement” (ASC 820) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2 or Level 3 measurements for the year ended December 31, 2020. The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019 (in thousands): Fair Value Measurements as of December 31, 2020 Using Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 707 $ — $ — $ 707 Equity investment $ — $ — $ 9,909 $ 9,909 Fair Value Measurements as of December 31, 2019 Using Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 707 $ — $ — $ 707 Minority interest investments - long-term $ — $ — $ 22 $ 22 Equity investment $ — $ — $ 11,501 $ 11,501

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Notes)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6 — PROPERTY AND EQUIPMENT Property and equipment consisted of the following at December 31 (in thousands): 2020 2019 Laboratory equipment $ 70,189 $ 60,486 Leasehold improvements 45,784 43,471 Computer equipment 4,034 3,916 Purchased software 22,981 22,621 Furniture and fixtures 6,081 5,924 Assets on loan/rental 32,544 28,946 181,613 165,364 Less: Accumulated depreciation (117,467) (99,849) $ 64,146 $ 65,515 Depreciation expense was $18.4 million and $16.5 million for the years ended December 31, 2020 and 2019, respectively.

GOODWILL

GOODWILL	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure [Text Block]	NOTE 7 — GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amount of goodwill during the period are as follows (in thousands): December 31, 2020 December 31, 2019 Balance at beginning of period $ 118,145 $ 118,127 Flow cytometry acquisition $ — $ 18 Balance at end of period $ 118,145 $ 118,145

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	A portion of the Company’s goodwill is not expected to be deductible for tax purposes. The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives): Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2019 Balance as of December 31, 2018 $ 98,469 $ 23,819 $ 10,655 $ 24,013 $ 156,956 Flow cytometry acquisition purchase price allocation adjustments (116) (428) 1,154 (4,016) (3,406) Balance as of December 31, 2019 98,353 23,391 11,809 19,997 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2018 (40,501) (9,036) (2,271) — (51,808) Amortization expense (7,784) (2,428) (1,194) — (11,406) Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Net balance as of December 31, 2019 $ 50,068 $ 11,927 $ 8,344 $ 19,997 $ 90,336 Weighted average life (in years) 11 10 10 2020 Balance as of December 31, 2019 $ 98,353 $ 23,391 $ 11,809 $ 19,997 $ 153,550 Completion of IPR&D projects 2,687 (2,687) — Balance as of December 31, 2020 101,040 23,391 11,809 17,310 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Amortization expense (7,919) (2,427) (1,194) — (11,540) Accumulated amortization balance as of December 31, 2020 (56,204) (13,891) (4,659) — (74,754) Net balance as of December 31, 2020 $ 44,836 $ 9,500 $ 7,150 $ 17,310 $ 78,796 Weighted average life (in years) 11 10 10 The Company currently has two IP R&D projects. The first relates to the development of the next generation VERIGENE System, VERIGENE II. The Company is targeting the commercial launch of the VERIGENE II System in 2021. The second is a defensive IP R&D project related to the Company’s next generation xMAP System, xMAP INTELLIFLEX, which the Company currently believes will launch commercially in the first half of 2021. The next generation Guava System (Guava Next Gen System), acquired as part of the Company’s acquisition of EMD Millipore Corporation’s flow cytometry portfolio, was launched commercially in the second quarter of 2020 and transferred from IP R&D to finite-lived technology, trade secrets and know-how and is being amortized. The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands): 2020 $ 11,316 2021 10,070 2022 9,721 2023 9,721 2024 8,188 Thereafter 12,470 $ 61,486

ACCRUED LIABILITIES (Notes)

ACCRUED LIABILITIES (Notes)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 9 — ACCRUED LIABILITIES Accrued liabilities consisted of the following as of December 31 (in thousands): 2020 2019 Compensation and employee benefits $ 33,992 $ 17,011 Dividends payable 4,711 4,104 Income and other taxes 7,058 1,538 Warranty costs 1,849 1,641 Royalties payable 782 1,335 Current operating lease liabilities 5,942 5,053 Convertible notes interest payable 996 — Other 1,035 1,190 $ 56,365 $ 31,872 Sales of certain of the Company’s systems are subject to a warranty. System warranties typically extend for a period of twelve months from the date of installation or no more than 15 months from the date of shipment. The Company estimates the amount of warranty claims on sold products that may be incurred based on current and historical data. The actual warranty expense could differ from the estimates made by the Company based on product performance. Warranty expenses are evaluated and adjusted periodically. The following table summarizes the changes in the warranty accrual (in thousands): Accrued warranty costs at December 31, 2017 $ 1,308 Warranty services provided (2,159) Accrual for warranty costs 2,752 Accrued warranty costs at December 31, 2018 1,901 Warranty services provided (2,868) Accrual for warranty costs 2,608 Accrued warranty costs at December 31, 2019 1,641 Warranty services provided (2,362) Accrual for warranty costs 2,570 Accrued warranty costs at December 31, 2020 $ 1,849

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Long-term Debt	NOTE 10 — CONVERTIBLE SENIOR NOTES In May 2020, the Company issued $260.0 million principal amount of Convertible Senior Notes due in May 2025 (Notes). The interest rates for the Notes is fixed at 3.00% per annum with interest payable semi-annually on May 15 and November 15 of each year, commencing on November 15, 2020. The Notes mature on May 15, 2025, unless earlier converted or repurchased in accordance with their terms prior to such date. Each $1,000 of principal amount of the Notes will initially be convertible into 22.8918 shares of the Company's common stock, which is equivalent to an initial conversion price of approximately $43.68 per share. The initial conversion price for each of the Notes is subject to adjustment upon the occurrence of certain specified events. On December 3, 2020, we announced that our Board declared an increased quarterly cash dividend of $0.10 per share of common stock to be paid to shareholders of record as of the close of business on December 23, 2020 with a payment date of January 14, 2021. This increase in the dividend adjusted the conversion price to $43.67 per share, or 22.9009 shares of the Company's common stock for each $1,000 of principal amount of the Notes. Holders may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding November 15, 2024 only under the following circumstances: • during any calendar quarter commencing after the calendar quarter ending on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; • during the five business day period after any five consecutive trading day period (Measurement Period) in which the trading price (as defined in the relevant indenture governing the Notes) per $1,000 principal amount of Notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; or • upon the occurrence of specified corporate events as set forth in the indenture governing the Notes. On or after November 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election. The Company currently intends to settle the principal amount of the Notes in cash, and settle any excess amount with shares of the Company’s common stock, upon conversion. As of December 31, 2020, the Notes were not yet convertible. If a fundamental change (as defined in the relevant indenture governing the Notes) occurs prior to the maturity date, holders of each of the Notes may require the Company to repurchase all or a portion of their Notes for cash at a repurchase price equal to 100% of the principal amount of the Notes, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date. In accounting for the issuance of the Notes, the Company separated each of the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value, as of the date of issuance, of a similar debt without the conversion feature. The effective interest rate used for the liability component was 8.50%. The liability component of the Notes is recorded in long-term debt, and the interest payable within the next twelve months is recorded in accrued liabilities on the Condensed Consolidated Balance Sheets as of December 31, 2020. The carrying amount of the equity component representing the conversion feature was determined by deducting the fair value of the liability components from the total initial proceeds. The difference between the par amount of the Notes and the carrying amount of the liability component represents debt discounts that are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The equity components are not remeasured as long as they continue to meet the conditions for equity classification. In accounting for the $7.7 million of issuance costs related to the Notes, the Company allocated the total amount of issuance costs incurred to the liability and equity components in proportion to the allocation of the proceeds from issuance to the liability and equity components. Issuance costs attributable to the liability components are amortized to interest expense over the respective terms of the Notes using the effective interest rate method. The issuance costs attributable to the equity components were netted against the respective equity components in additional paid-in capital. Issuance costs attributable to the liability component, totaling $6.0 million, are being amortized to expense over the expected life of the Notes using the effective interest method. Issuance costs attributable to the equity component related to the conversion feature, totaling $1.7 million, were netted with the equity component. The Notes consist of the following: As of December 31, 2020 Liability component: Principal $ 260,000 Unamortized debt discount (51,352) Unamortized debt issuance costs (5,512) Net carrying amount $ 203,136 Equity component: Net carrying amount $ 41,950 The following table sets forth total interest expense recognized related to the Notes for the years ended December 31 (in thousands): 2020 2019 Contractual interest expense $ 4,940 $ — Amortization of debt issuance costs 531 — Amortization of debt discount 6,002 — Total $ 11,473 $ — As of December 31, 2020, the remaining period over which the debt discount and debt issuance costs will be amortized was 4.4 years. Convertible Note Hedge and Warrant Transactions Concurrent with the offering of the Notes, the Company entered into privately negotiated convertible note hedge transactions (Convertible Note Hedge Transactions) with certain financial institutions (Option Counterparties) related to the issuance of the Notes. The Convertible Note Hedge Transactions are generally expected to reduce the potential dilution to the Company’s common stock upon any conversion of Notes or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes. The Company also entered into separate privately negotiated warrant transactions (Warrant Transactions) with each of the Option Counterparties pursuant to which the Company issued Warrants that will be exercisable into a number of shares of the Company’s common stock at a price per share equal to $69.89, subject to certain adjustments under the terms of the Warrant Transactions. The Warrant Transactions could separately have a dilutive effect on the Company’s common stock if the market value per share of the Company’s common stock exceeds the applicable strike price of the Warrants. However, subject to certain conditions, the Company may elect to settle the Warrants in cash. The Convertible Note Hedge Transactions and the Warrant Transactions are separate transactions, in each case, entered into by the Company with the same Option Counterparties and are not part of the terms of the Notes and will not affect any holder’s rights under the Notes. The holders of the Notes will not have any rights with respect to the Convertible Note Hedge Transactions or Warrant Transactions. The Company used approximately $34.7 million of the net proceeds of the issuance of the Notes to pay the costs of the Convertible Note Hedge Transactions, after such cost was partially offset by the proceeds to the Company from the sale of the Warrants in the Warrant Transactions. The Convertible Note Hedge Transactions and Warrant Transactions do not meet the criteria for derivative accounting as they are indexed to the Company's stock. The amounts paid for the Convertible Note Hedge Transactions and the proceeds received from the Warrant Transactions have been included as a net reduction to additional paid-in capital.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 11 — INCOME TAXES The components of income before income taxes for the years ended December 31 are as follows (in thousands): 2020 2019 2018 Domestic $ (33,631) $ (31,314) $ 7,242 Foreign 62,571 21,812 21,069 Total $ 28,940 $ (9,502) $ 28,311 The components of the provision (benefit) for income taxes attributable to continuing operations for the years ended December 31 are as follows (in thousands): 2020 2019 2018 Current: Federal $ (7) $ 821 $ (3,318) Foreign 6,689 951 515 State 179 (163) 600 Total current expense (benefit) $ 6,861 $ 1,609 $ (2,203) Deferred: Federal (2,913) (10,179) 6,351 Foreign 8,886 4,597 5,271 State 936 (1,691) 384 Total deferred expense (benefit) 6,909 (7,273) 12,006 Total provision (benefit) for income taxes $ 13,770 $ (5,664) $ 9,803 The provision (benefit) for income taxes differs from the amount computed by applying the statutory federal rate to pretax income as follows (in percentages): Year Ended December 31, 2020 2019 2018 Statutory tax rate 21.0 % 21.0 % 21.0 % State taxes, net of federal benefit (3.5) % 9.6 % 3.0 % Permanent items (2.4) % (1.6) % 2.6 % Effect of foreign operations 10.2 % (11.7) % 3.4 % Research and incentive tax credit generated (7.7) % 18.9 % (8.7) % Valuation allowance 9.1 % 0.8 % 0.4 % Income tax reserves 1.0 % 67.3 % 24.7 % Remeasurement U.S. deferreds 0.0 % 0.0 % (0.3) % Transition tax 0.0 % (5.3) % (16.6) % Foreign earnings withholding tax 0.1 % 6.6 % (7.9) % Global intangible low-taxed income 18.6 % (44.4) % 5.7 % Other measurement period Tax Act adjustments 0.0 % 0.0 % 2.6 % Canadian income tax audit 0.0 % 0.0 % 4.8 % Other 1.2 % (1.0) % (0.1) % 47.6 % 60.2 % 34.6 % The Company accounts for income taxes using the asset and liability method in accordance with ASC 740 “Income Taxes” (ASC 740) . Under this method, deferred income taxes are recognized for the future tax consequences of differences between the tax and financial accounting bases of assets and liabilities at the end of each reporting period. Deferred income taxes are based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. Significant components of the Company’s deferred tax assets and liabilities as of December 31 are as follows (in thousands): 2020 2019 Deferred tax assets: Accrued liabilities and other $ 7,479 $ 4,577 Net operating loss and credit carryforwards 40,966 52,141 Deferred revenue 2,119 1,023 Operating lease liability 4,060 5,023 Stock compensation and other 7,542 7,791 Bond hedge 12,103 — Gross deferred tax assets 74,269 70,555 Valuation allowance (16,882) (17,906) Total deferred tax assets $ 57,387 $ 52,649 Deferred tax liabilities: Accrued liabilities and other $ (4,230) $ (1,287) Depreciation and amortization (15,710) (18,443) Operating lease right-of-use assets (3,649) (4,550) Equity method investment (279) (667) Convertible debt (12,442) Total deferred tax liabilities (36,310) (24,947) Net deferred tax assets $ 21,077 $ 27,702 The Company has established a valuation allowance against a portion of its remaining deferred tax assets because it is more likely than not that certain deferred tax assets will not be realized. In determining whether deferred tax assets are realizable, the Company considered numerous factors including historical profitability, the amount of future taxable income and the existence of taxable temporary differences that can be used to realize deferred tax assets. The valuation allowance decreased approximately $1.0 million in 2020 from 2019 primarily due to releasing valuation allowance of $3.6 million against deferred tax assets of certain state net operating loss carryforwards, state research credit carryforwards, and deferred tax assets for stock compensation, and recording additional valuation allowance on the deferred tax assets of certain state net operating loss carryforwards of $2.6 million. The Company’s valuation allowance is primarily offsetting certain state net operating loss and state tax credit carryforwards, and certain stock based compensation. We anticipate portions of our deferred tax assets will not be realized under the provisions of Section 162(m) of the Tax Act which limits the deductibility of executive compensation. At December 31, 2020, the Company had gross federal, state and foreign net operating loss carryforwards of approximately $41.9 million, $283.8 million, and $6.1 million, respectively. These losses expire beginning in 2021. Federal and state net operating losses of approximately $41.9 million and $268.9 million, respectively, were acquired as part of the acquisitions of U.S. companies. These acquired net operating losses are subject to annual limitations due to the “change of ownership” provisions of Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The Company has federal, state and foreign credit carryforwards of approximately $8.6 million, $3.4 million, and $2.6 million, respectively. These credits begin to expire in 2023, except for approximately $1.1 million of state research credits which have an indefinite carryforward period. Certain of these credits are subject to annual limitations under the change in ownership provisions. The excess of financial reporting basis over tax basis of the Company’s foreign subsidiaries is considered permanently reinvested with the exception of certain earnings of the Canadian subsidiary. The cumulative amount of excess financial reporting basis of the Company’s non-U.S. subsidiaries was approximately $14.3 million at December 31, 2020, $22.5 million at December 31, 2019 and $3.8 million at December 31, 2018. Since the Company does not intend to permanently reinvest portions of its previously taxed Canadian earnings, it has recorded a deferred tax liability of approximately $30 thousand related to state income taxes associated with the ultimate repatriation from Canada to the U.S. of these previously taxed earnings. Beginning January 1, 2018, the Tax Act implemented a territorial tax system in the U.S. such that the income earned by the Company’s non-U.S. subsidiaries will be subject to a 100% dividend received deduction, with certain exceptions. We have not recognized a deferred tax liability related to withholding taxes or state income taxes on the excess financial reporting basis of our other foreign subsidiaries because the Company currently intends to reinvest earnings of these subsidiaries in operations outside the U.S. Determination of the amount of the unrecognized deferred tax liability on these unremitted earnings is not practicable. As of December 31, 2020 and December 31, 2019, the Company had recorded gross unrecognized tax benefits of approximately $3.7 million and $3.4 million, respectively. All of the unrecognized tax benefits as of December 31, 2020, if recognized, would impact the effective tax rate. The Company recognizes interest expense and penalties associated with uncertain tax positions as a component of income tax expense. During the years ended December 31, 2020 and 2019, the Company recognized approximately $26 thousand and $1 thousand in tax related interest and penalties, respectively. Reserves for interest and penalties as of December 31, 2020 and 2019 are not significant as the Company has net operating loss carryovers and tax credit carryforwards. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): 2020 2019 Balance at beginning of year $ 3,423 $ 9,721 Additions based on tax positions related to the current year 311 342 Additions for tax positions of prior years — 398 Reductions for tax positions of prior years (30) (7,038) Balance at end of year $ 3,704 $ 3,423 As of December 31, 2020, there were no unrecognized tax benefits that we expect would change significantly over the next 12 months. The Company files U.S., state, and foreign income tax returns in jurisdictions with varying statutes of limitations. In the United States and Canada, the statute of limitations with respect to the federal income tax returns for tax years after 2015 are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the 2015 tax year and make adjustments to these net operating loss carryforwards. In the fourth quarter of 2020, the IRS completed its audit of the Company's 2016 tax return with no material adjustments. In addition, during 2020 the IRS began auditing the Company's 2017 tax return with respect to certain limited issues. The IRS completed its audit of the Company's 2017 tax return in the fourth quarter of 2020 with no tax adjustments. We are not under audit in any major taxing jurisdictions at this time.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE 12 — EARNINGS PER SHARE A reconciliation of the denominators used in computing per share net income (EPS) is as follows (in thousands, except per share amounts): Year Ended December 31, 2020 2019 2018 Basic: Net income (loss) $ 15,170 $ (3,838) $ 18,508 Less: allocation to participating securities (297) 65 (312) Net income (loss) attributable to common stockholders $ 14,873 $ (3,773) $ 18,196 Weighted average common stock outstanding 45,102 44,148 43,727 Net income (loss) per share attributable to common stockholders $ 0.33 $ (0.09) $ 0.42 Diluted: Net income (loss) $ 15,170 $ (3,838) $ 18,508 Less: allocation to participating securities (298) 63 (311) Net income (loss) attributable to common stockholders $ 14,872 $ (3,775) $ 18,197 Weighted average common stock outstanding 45,102 44,148 43,727 Effect of dilutive securities: stock options and awards 718 — 564 Weighted-average shares used in computing net income (loss) per share 45,820 44,148 44,291 Net income (loss) per share attributable to common stockholders $ 0.32 $ (0.09) $ 0.41 Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock awards (RSAs) and stock options to acquire 1,620,252 shares, 1,271,248 shares, and 619,113 shares for the years ended December 31, 2020, 2019 and 2018, respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive. We apply the two-class method of computing earnings per share, which requires the calculation of separate earnings per share amounts for our non-vested, time-based restricted stock awards with non-forfeitable dividends and for our common stock. Our non-vested, time-based restricted stock awards with non-forfeitable dividends are considered securities which participate in undistributed earnings with common stock. Under the two-class computation method, net losses are not allocated to participating securities unless the holder of the security has a contractual obligation to share in the losses. Our non-vested, time-based restricted stock awards with non-forfeitable dividends do not have such an obligation so they are not allocated losses.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 13 — STOCKHOLDERS’ EQUITY, EMPLOYEE BENEFIT PLANS AND STOCK-BASED COMPENSATION Preferred Stock The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders. At December 31, 2020 and 2019, there was no preferred stock issued and outstanding. Dividends I n February 2017, the Board of Directors initiated a cash dividend program under which the Company began paying a regular quarterly cash dividend. The following table shows cash dividends declared, recorded, and paid (or to be paid) in the periods shown: Date Paid or Dividends Declared per Share Twelve Months Ending Date Declared Date Payable December 31, 2018 January 24, 2018 March 23, 2018 April 13, 2018 $ 0.06 May 18, 2018 June 22, 2018 July 13, 2018 $ 0.06 September 11, 2018 September 21, 2018 October 12, 2018 $ 0.06 December 11, 2018 December 22, 2018 January 10, 2019 $ 0.06 December 31, 2019 February 8, 2019 March 21, 2019 April 11, 2019 $ 0.06 May 21, 2019 June 20, 2019 July 11, 2019 $ 0.06 July 31, 2019 September 26, 2019 October 17, 2019 $ 0.09 December 6, 2019 December 19, 2019 January 15, 2020 $ 0.09 December 31, 2020 February 18, 2020 March 19, 2020 April 9, 2020 $ 0.09 May 22, 2020 June 18, 2020 July 9, 2020 $ 0.09 September 10, 2020 September 24, 2020 October 15, 2020 $ 0.09 December 3, 2020 December 23, 2020 January 14, 2021 $ 0.10 The Company’s current intent is to pay a continuing dividend on a quarterly basis. However, future declaration of dividends is subject to the final determination of the Company’s Board of Directors. Stock-Based Compensation At December 31, 2020, the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Luminex Corporation 2018 Equity Incentive Plan (Equity Incentive Plan) which was approved at the Company’s Annual Meeting on May 17, 2018. No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (2000 Plan), the 2001 Broad-Based Stock Option Plan (2001 Plan) or the 2006 Equity Incentive Plan (2006 Plan). In addition, at December 31, 2020, the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (ESPP), which was approved at the Company’s Annual Meeting on May 17, 2012 and amended at the Company’s Annual Meeting on May 18, 2017. Equity Incentive Plans Under the Company’s Equity Incentive Plan and, the 2006 Plan, certain employees, consultants and non-employee directors have been granted RSAs, restricted stock units (RSUs) and options to purchase shares of common stock. The options, RSAs, and RSUs generally vest in installments over a three to five year period, and the options expire either seven or ten years after the date of grant. The ESPP provides for the granting of rights to certain employees of the Company to defer an elected percentage, up to 15%, of their base salary through the purchase of the Company’s common stock, discounted by 15%. As of December 31, 2020, there were approximately 2,400,000 shares authorized for future issuance under the Company’s Equity Incentive Plan and 83,044 shares eligible for purchase pursuant to the terms and conditions of the ESPP as more fully described below. The Equity Incentive Plan, the 2006 Plan and the ESPP are administered by the Compensation Committee of the Board of Directors. The Compensation Committee has the authority to determine the terms and conditions under which awards will be granted from the Equity Incentive Plan, including the number of shares, vesting schedule and term, as applicable. Any option exercise prices, as set forth in the Equity Incentive Plan, will be equal to the fair market value on the date of grant. Under certain circumstances, the Company may repurchase previously granted RSAs and RSUs. On February 27, 2020 and February 21, 2019, the Compensation Committee approved awards of stock options (the Performance Options) to the Company’s named executive officers and certain other executives that vest over four years based on achievement of certain operating profit and revenue targets for each of 2020 and 2019, respectively. The Performance Options have an exercise price equal to the closing market price for the Company’s common stock on the Nasdaq Global Select Market on the date of grant (March 12, 2020 and 2019, respectively) and expire seven years from the date of grant. The Performance Options were measured over a one-year performance period ending on December 31, 2020 and 2019, respectively. Following the end of the applicable fiscal year, the Committee determined the number of Performance Options which were eligible to vest based upon the level of achievement of an established Company performance goal (the Company Financial Goal). If the Company failed to meet the threshold performance for the performance period, no Performance Options would be eligible to vest. Minimum vesting for minimum threshold performance started at 30% of the target value for the Company Financial Goal. If the Company’s performance exceeded the target performance, the recipient may receive additional Performance Options above the target number, subject to a maximum of 200% of the target award. The Company’s financial performance resulted in delivery of 200% and 83% of the number of target Performance Options granted for 2020 and 2019, respectively. The Performance Options that are eligible to vest after the determination date will vest 25% on each of the first four anniversaries of the grant date. In the event of a change of control of the Company before the end of the performance period, the Performance Options will automatically vest based on the greater of actual achievement of the pro-rated Company Financial Goal as of the date of the change of control or 100% of target performance, as determined by the Committee in its sole discretion. The Performance Options are exercisable into shares of the Company’s common stock. Accounting for Stock Compensation Stock-based compensation costs are generally based on the fair value calculated from the Black-Scholes option-pricing model on the date of grant for stock options, performance options and market value on the date of grant for RSAs. The fair values of stock and stock options are amortized as compensation expense on a straight-line basis over the vesting period of the grants. In accordance with ASC 718, the Company evaluates the assumptions used in the Black-Scholes model at each grant date using a consistent methodology for computing expected volatility, expected term and risk-free rate of return. Calculation of expected volatility is based on historical volatility. The expected life is calculated using the contractual term of the options as well as an analysis of the Company’s historical exercises of stock options and performance options. The estimate of the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on our history and expectation of dividend payouts at the time of grant. The assumptions used are summarized in the following table: 2020 2019 2018 Dividend yield 1.5 % 0.9 % 1.2 % Expected volatility 0.3 0.4 0.4 Risk-free rate of return 0.9 % 2.6 % 2.7 % Expected life of a 10 year contractual term option 7 years 7 years 7 years Expected life of a 7 year contractual term option 4.75 years 4.88 years 4.88 years Weighted average fair value at grant date $ 6.17 $ 7.69 $ 8.23 As part of the requirements of ASC 718, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures is based on historical forfeiture performance and will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of evaluation and will also impact the amount of stock compensation expense to be recognized in future periods. The Company’s stock option activity for the year ended December 31, 2020 is as follows: Stock Options Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2019 3,793 $ 20.17 Granted 1,508 23.09 Exercised (998) 18.18 Canceled or expired (550) 24.43 Outstanding at December 31, 2020 3,753 $ 21.25 4.48 $ 7,633 Vested at December 31, 2020 and expected to vest 3,687 $ 21.22 4.45 $ 7,623 Exercisable at December 31, 2020 1,519 $ 19.12 3.00 $ 6,248 During the years ended December 31, 2020, 2019 and 2018, the total exercise intrinsic value of stock options exercised was $16.2 million, $0.4 million and $1.3 million, respectively, and the total fair value of stock options that vested was $10.6 million, $11.9 million and $12.7 million, respectively. Exercise intrinsic value represents the difference between the market value of the Company’s common stock at the time of exercise and the price paid by the employee to exercise the options. The Company had $10.5 million of total unrecognized compensation costs related to stock options at December 31, 2020 that are expected to be recognized over a weighted-average period of 2.57 years. The Company’s restricted share activity for the year ended December 31, 2020 is as follows: Restricted Stock Awards Shares Weighted Average Grant Price Non-vested at December 31, 2019 810 $ 22.28 Granted 416 23.26 Vested (295) 21.49 Cancelled or expired (38) 22.65 Non-vested at December 31, 2020 893 $ 22.98 Restricted Stock Units Shares Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value (in thousands) Non-vested at December 31, 2019 522 Granted 100 Vested (45) Cancelled or expired (7) Non-vested at December 31, 2020 570 1.09 $ 13 Vested at December 31, 2020 and expected to vest 563 1.05 $ 13 Exercisable at December 31, 2020 403 0.00 $ 9 As of December 31, 2020, there was $18.7 million of unrecognized compensation cost related to RSAs and RSUs. That cost is expected to be recognized over a weighted average-period of 2.17 years. The total fair value of restricted shares vested during the year ended December 31, 2020, 2019 and 2018 was $7.3 million, $6.0 million and $6.7 million, respectively. RSAs and RSUs may be granted at the discretion of the Compensation Committee of the Board of Directors under the Equity Incentive Plan in connection with the hiring or retention of key employees and are subject to certain conditions. Restrictions expire at certain dates after the grant date in accordance with specific provisions in the applicable agreement. During the year ended December 31, 2020, the Company awarded 416,142 shares of RSAs, which had a fair value at the date of grant ranging from $23.05–$31.65. During the year ended December 31, 2019, the Company awarded 413,967 shares of RSAs, which had a fair value at the date of grant ranging from $20.04–$24.43. During the year ended December 31, 2018, the Company awarded 387,436 shares of RSAs, which had a fair value at the date of grant ranging from $20.33–$29.33. During the year ended December 31, 2020, the Company awarded 99,584 shares of RSUs and dividend equivalents, which had a fair value at the date of grant ranging from $23.09–$31.65. During the year ended December 31, 2019, the Company awarded 120,498 shares of RSUs and dividend equivalents, which had a fair value at the date of grant ranging from $21.01–$24.43. During the year ended December 31, 2018, the Company awarded 95,127 shares of RSUs, which had a fair value at the date of grant ranging from $21.98–$26.39. Compensation under these RSAs and RSUs was charged to expense over the restriction period and amounted to $9.2 million, $8.2 million, and $6.2 million in 2020, 2019 and 2018, respectively. There were no significant stock compensation costs capitalized into assets as of December 31, 2020, 2019 or 2018. The Company received $18.0 million, $1.7 million and $2.8 million for the exercise of stock options during the years ended December 31, 2020, 2019 and 2018, respectively. Cash was not used to settle any equity instruments previously granted. The Company issued shares pursuant to grants relating to each of the Equity Incentive Plan, the 2006 Plan and 2000 Plan from reserves upon the exercise of stock options and vesting of RSAs. The following are the stock-based compensation costs recognized in the Company’s consolidated statements of comprehensive income (in thousands): Year Ended December 31, 2020 2019 2018 Cost of revenue $ 2,332 $ 2,028 $ 1,715 Research and development 2,027 1,635 1,409 Selling, general and administrative 10,493 9,535 9,102 Stock-based compensation costs reflected in net income (loss) $ 14,852 $ 13,198 $ 12,226 Employee Stock Purchase Plan In May 2012, the Company’s stockholders approved the ESPP, which provides for the purchase of up to 500,000 shares of the Company’s common stock by eligible employees. In May 2017, the Company’s stockholders approved an amendment to the ESPP Plan, which increased the shares available under the ESPP by 341,744 shares. The ESPP period is semi-annual and allows participants to purchase the Company’s common stock at 85% of the lesser of (i) the closing market value per share of the common stock on the first trading date of the option period or (ii) the closing market value per share of the common stock on the last trading date of the option period. As of December 31, 2020, 2019 and 2018, 758,700 shares, 631,553 shares and 518,111 shares, respectively had been issued out of the ESPP. The related stock-based compensation expense was $0.7 million, $0.6 million and $0.5 million for 2020, 2019 and 2018, respectively. The Company uses the Black-Scholes model to estimate the fair value of shares to be issued under the ESPP as of the grant date using the following weighted average assumptions: 2020 2019 2018 Assumptions: Risk-free interest rates 0.18 % 2.55 % 2.1 % Expected life 0.5 years 0.5 years 0.5 years Expected volatility 0.3471 0.35 0.44 Dividend yield 1.454 % 0.942 % 1.2 % Reserved Shares of Common Stock At December 31, 2020 and 2019, the Company had reserved 6,808,668 and 8,349,808 shares of common stock, respectively, for the issuance of common stock upon the exercise of options, issuance of RSAs, RSUs, purchase of common stock pursuant to the ESPP or other awards issued pursuant to the Company’s equity plans and arrangements. The following table summarizes the reserved shares by plan as of December 31, 2020: Options and RSUs Outstanding Shares Available for Future Issuance Total Shares Reserved Equity Incentive Plan 4,339,804 2,385,820 6,725,624 ESPP — 83,044 83,044 4,339,804 2,468,864 6,808,668 Employee Savings Plans and Other Benefit Plans Effective January 1, 2001, the Company began sponsoring a retirement plan authorized by section 401(k) of the Internal Revenue Code for the Company’s employees in the United States. In accordance with the 401(k) plan, all employees are eligible to participate in the plan on the first day of the month following the commencement of full time employment. For 2020, 2019 and 2018, each employee could contribute a percentage of compensation up to a maximum of $19,500, $19,000, and $18,500 per year, respectively, with the Company matching 50% of each employee’s contributions. Effective January 1, 2010, the Company began contributing to a deferred profit sharing plan for its Canadian employees. All Canadian employees are eligible to participate in the plan. The Company’s contributions to these plans for 2020, 2019 and 2018 were $5.4 million, $5.1 million and $4.0 million, respectively. Several of the Company’s Netherlands employees are covered by a defined benefit plan. The cost and total liability to the Company is not material. Effective January 1, 2011, all of the Company’s new hires in the Netherlands are eligible to participate in a defined contribution plan.
Preferred Stock [Text Block]	Preferred Stock The Company’s Board of Directors has the authority to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences and the number of shares constituting any series or the designation of such series, without further vote or action by the Company’s stockholders. At December 31, 2020 and 2019, there was no preferred stock issued and outstanding.
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Stock-Based Compensation At December 31, 2020, the Company has one stock-based employee compensation plan pursuant to which grants may be made: the Luminex Corporation 2018 Equity Incentive Plan (Equity Incentive Plan) which was approved at the Company’s Annual Meeting on May 17, 2018. No further grants shall be made pursuant to the 2000 Long-Term Incentive Plan (2000 Plan), the 2001 Broad-Based Stock Option Plan (2001 Plan) or the 2006 Equity Incentive Plan (2006 Plan). In addition, at December 31, 2020, the Company has one plan pursuant to which discount purchases may be made by the participants in such plan: the Luminex Corporation Employee Stock Purchase Plan (ESPP), which was approved at the Company’s Annual Meeting on May 17, 2012 and amended at the Company’s Annual Meeting on May 18, 2017.

CONTINGENCIES

CONTINGENCIES	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 15 — COMMITMENTS AND CONTINGENCIES Leases We have leased all of our research, manufacturing and office space and have entered into various other leases in conducting our business. Our leases have remaining lease terms of one year to six years, and some of our leases include options to extend the leases for up to ten years, tenant improvement allowances, rent holidays and rent escalation clauses. As the Company’s leases do not provide an implicit rate, we have used an estimated incremental borrowing rate of 5.75%, based on the information available at the commencement date in determining the present value of lease payments. The components of the lease expense were as follows (in thousands): Twelve Months Ended December 31, 2020 2019 2018 Operating lease cost (a) $ 9,792 $ 9,434 $ 7,032 (a) Includes short-term lease expense costs, which were immaterial in the years ended December 31, 2020, 2019 and 2018 Supplemental cash flow information related to leases was as follows (in thousands): Twelve Months Ended Twelve Months Ended December 31, 2020 December 31, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 7,072 $ 6,553 Supplemental balance sheet information related to leases was as follows (in thousands): December 31, 2020 December 31, 2019 Operating leases: Operating lease right-of-use assets $ 17,768 $ 20,439 Operating lease liabilities $ 19,308 $ 22,235 Weighted average remaining lease term 3.52 years 4.36 years Weighted average discount rate 5.75 % 5.75 % Minimum annual lease commitments as of December 31, 2020 under non-cancellable leases for each of the next five years and in the aggregate were as follows (in thousands): Operating Leases 2021 $ 7,206 2022 5,540 2023 4,507 2024 3,177 2025 945 Thereafter — Total lease payments 21,375 Less: imputed interest (2,067) Lease liabilities at December 31, 2020 $ 19,308 These non-cancellable lease commitments related to facilities include certain rent escalation provisions which have been included in the minimum annual rental commitments shown above. These amounts are recorded to expense on a straight-line basis over the life of the lease. In addition, some of the Company’s leases contain options to renew the lease for five to ten years at the then prevailing market rental rate, right of first refusal to lease additional space that becomes available, or leasehold improvement incentives. Non-Cancellable Purchase Commitments As of December 31, 2020 the Company had approximately $68.1 million in purchase commitments primarily with several of its inventory suppliers as well as other operating commitments. Certain of our supply agreements require purchase and delivery of minimum amounts of components through 2020, and purchases under these arrangements were $0.5 million, $0.8 million and $2.2 million for the years ended December 31, 2020, 2019 and 2018, respectively. Employment Contracts The Company has entered into employment contracts with certain of its key executives. Generally, certain amounts may become payable in the event the Company terminates the executives’ employment without cause or the executive resigns for good reason. Legal Proceedings In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. When and if it appears probable in management’s judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements. If only a range of estimated losses can be estimated, we record an amount within the range that, in management’s judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided.

GUARANTEES (Notes)

GUARANTEES (Notes)	12 Months Ended
	Dec. 31, 2020
Guarantees and Product Warranties [Abstract]
Guarantees [Text Block]	NOTE 16 — GUARANTEES The terms and conditions of the Company’s development and supply and license agreements with its strategic partners generally provide for a limited indemnification of such partners, arising from the sale of Luminex systems and consumables, against losses, expenses and liabilities resulting from third-party claims based on an alleged infringement on an intellectual property right of such third party. The terms of such indemnification provisions generally limit the scope of and remedies for such indemnification obligations to a multiple of amounts paid by such strategic partner to Luminex during the previous annual period(s). To date, the Company has not had to reimburse any of its strategic partners for any losses arising from such indemnification obligations.

GEOGRAPHIC INFORMATION (Notes)

GEOGRAPHIC INFORMATION (Notes)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Sales to Customers Property and Equipment, net 2020 2019 2018 2020 2019 2018 Domestic $ 325,781 $ 252,381 $ 261,726 $ 61,755 $ 63,180 $ 63,382 Foreign: Europe 48,635 36,625 21,672 89 178 394 Asia 30,018 32,220 21,603 577 442 519 Canada 5,293 4,775 1,725 1,715 1,993 Other 12,962 8,119 6,042 — — — $ 417,396 $ 334,638 $ 315,818 $ 64,146 $ 65,515 $ 66,288

RECENT ACCOUNTING (Notes)

RECENT ACCOUNTING (Notes)	12 Months Ended
	Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 18 — RECENT ACCOUNTING PRONOUNCEMENTS Recently adopted accounting guidance In June 2016, the FASB issued guidance on financial instruments and related credit losses. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The statement of comprehensive income reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2020. The Company adopted the new standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company does not have a history of significant credit losses and this guidance did not have a material impact on its consolidated financial statements. Recent accounting guidance not yet adopted In December 2019, the FASB issued final guidance that simplifies the accounting for income taxes by eliminating some exceptions to the general approach in ASC 740, Income Taxes. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance includes provisions for investment company reporting modernization, amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, and is applicable for the Company in fiscal 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.

REVENUE RECOGNITION (Notes)

REVENUE RECOGNITION (Notes)	12 Months Ended
	Dec. 31, 2020
Revenue Recognition and Deferred Revenue [Abstract]
Revenue Recognition, Deferred Revenue [Policy Text Block]	NOTE 14 — REVENUE RECOGNITION Contract assets are included within Accounts receivables, net and contract liabilities are included in Deferred revenue on the Company’s Balance Sheet. The following table presents the opening and closing balances of the Company’s contract assets and liabilities for the twelve months ended December 31, 2020 (in thousands): Balance at Balance at December 31, 2019 Contract assets: Unbilled receivables - Royalties $ 12,054 $ 12,257 Contract liabilities - short-term: Deferred revenue - Service $ 9,346 $ 7,771 Deferred revenue - Licenses 197 207 Deferred revenue - Instruments 78 2 Deferred revenue - Other 426 234 Total Contract liabilities - short-term $ 10,047 $ 8,214 Contract liabilities - long-term: Deferred revenue - Service $ 1,190 $ 968 Deferred revenue - Licenses 468 665 Total Contract liabilities - long-term $ 1,658 $ 1,633 During the twelve months ended December 31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the period (in thousands): Year Ended December 31, 2020 Revenue recognized in the period: Amounts included as contract liabilities at the beginning of the period $ 9,387 Performance obligations satisfied in previous periods -

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Business Description and Accounting Policies [Text Block]	NOTE 1 — DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company’s proprietary technologies. Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company’s end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed. The Company primarily serves the life sciences industries by marketing products, including our specific testing equipment and assays, to various types of testing laboratories. As of December 31, 2020, the Company had 82 strategic partners, 54 of which have released commercialized reagent-based products utilizing the Company’s technology. Luminex and these partners have sold approximately 17,900 xMAP-based instruments in laboratories worldwide as of December 31, 2020, some of which may be retired or otherwise not in use. The Company’s remaining partners are in various stages of development and commercialization of products incorporating the Company’s technology. A primary focus for the Company’s growth is the development and sale of molecular diagnostic assays utilizing the Company’s proprietary MultiCode and VERIGENE technologies for use on the Company’s installed base of systems. The Company utilizes a direct sales model for sales of these products, which is intended to take advantage of the Company’s increasing installed base of instruments. Luminex’s assays are primarily focused on multiplexed applications for the human molecular clinical diagnostics market. Luminex’s assays are currently focused on three segments of the molecular diagnostic testing market: infectious disease, personalized medicine and human genetics. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements. Cash and Cash Equivalents Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased. Investments The Company determines the appropriate classification of its investments in equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Fair Value of Financial Instruments The fair values of financial instruments are determined by obtaining non-binding market prices from the Company’s third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, equity-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2020 and 2019. See Note 6 for further details concerning fair value measurements. Supplemental Cash Flow Statement Information (in thousands) Year Ended December 31, 2020 2019 2018 Cash paid during the period for taxes $ 2,141 $ 1,206 $ 2,214 Cash paid during the period for interest and penalties 3,969 29 17 Effect of acquisitions: Fair value of tangible assets acquired — 2,657 13,262 Liabilities assumed — (1,915) (5,082) Cost in excess of fair value of assets acquired — 18 32,647 Acquired identifiable intangible assets — 609 26,797 Deferred tax liabilities, net — 731 (4,433) In-process research and development — (4,016) 6,703 Total purchase price — (1,916) 69,894 Less cash and cash equivalents acquired — — 4,513 Net cash paid for business acquisition $ — $ (1,916) $ 65,381 Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral. One customer accounted for 10%, 12% and 14% of our total revenues in 2020, 2019 and 2018, respectively. Another customer accounted for 4%, 5% and 15% of our total revenues in 2020, 2019 and 2018, respectively. No other customer accounted for more than 10% of our total revenues in 2020, 2019 or 2018. Inventories Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company’s markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company’s policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company’s assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be above the lower of cost or net realizable value, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company’s operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value. Property and Equipment Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex’s xMAP, ARIES and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as “Assets on loan/rental.” Leases With the adoption of the new lease guidance effective January 1, 2019, the Company determines whether an agreement represents a lease and at commencement we evaluate each lease agreement to determine whether the lease is an operating or financing lease. The Company recorded an operating lease right-of-use asset and an operating lease liability on its balance sheet. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. For all lease agreements we combine lease and non-lease components. Leases with an initial term of twelve months or less are not recorded on the balance sheet. Goodwill and Other Intangible Assets Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2020. In 2020 and 2019, the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company’s annual test did not result in an impairment charge in 2020, as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2020, 2019 or 2018. Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned. Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made. Revenue Recognition, Receivables and Allowance for Doubtful Accounts Performance Obligations: Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company’s systems. The Company recognizes revenue when the customer obtains control of promised products or services, in an amount that reflects the consideration which the Company expects to receive in exchange for these products or services. To determine revenue recognition for arrangements, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation and recognizes as revenue when such performance obligation is satisfied. Revenue recognition typically occurs upon shipment or delivery to the customer depending upon the shipping terms. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost. Our customers do not typically have any contractual rights of return outside of our warranty provisions. The Company has allowed few returns to date and believes that returns of its products will be minimal in the future. Royalties: For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied. Royalty payments are typically received when our strategic partners report the end-user sales to the Company. Reagent Rentals: The Company provides systems and certain other hardware to customers through reagent rental agreements, under which the customers commit to purchasing minimum quantities of assays at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for assays. Revenue is recognized over the defined contract term as assays are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Under the guidance, the Company reclassified the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue. Warranties: The Company provides a limited, assurance-type warranty, typically for twelve months from installation for the systems sold to end customers and fifteen months for the systems sold to partners. The Company accrues for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. While the Company believes that adequate reserve has been made in the consolidated financial statements for product warranties, should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Warranty expenses are evaluated and adjusted periodically. License Revenues: The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third parties. These licenses are typically not distinct, as the customer cannot benefit from the license on its own, and do not have significant standalone functionality, but represent single performance obligations together with the sales of our consumables, systems and assays. The terms of these arrangements typically include payment to the Company of non-refundable, up-front license fees and can extend up to twenty years. Each of these payments results in license revenues which are recognized ratably over time and are included in other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. Deferred revenues related to these out-licensing agreements are shown in contract liabilities in Note 18, “Revenue Recognition”. Service Agreements: Revenue from extended service agreements is deferred when payment is received in advance of the performance obligation being satisfied or completed. Luminex provides an integrated service of maintenance and related activities for equipment sold to customers, where the nature of the overall promise is to provide a stand-ready service. As such, the performance obligation is recognized as a series of distinct service periods and the service revenue is recognized ratably over the term of each agreement. The extended service agreements typically range from one to four years and payment is typically received up-front. Reserves for Variable Consideration : Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts and any other allowances that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual requirements, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of each contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period when such variances become known. Receivables and Allowance for Doubtful Accounts: We recognize receivables when we have an unconditional right to payment, which represents the amount we expect to collect in a transaction and is most often equal to the transaction price in the contract. The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, which is based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together, as similar risk characteristics exist between them. On the rare occasion that interest is charged on trade receivables, it is recognized when received and there are no related fees and costs. Receivable balances are written off to the allowance for doubtful accounts when, in the judgment of management, they are considered uncollectible. The Company's credit losses have historically been within the Company’s expectations, but there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts. Product-Related Expenses The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising. Advertising expenses, which include trade shows and conventions, were approximately $1.4 million, $3.5 million and $2.8 million for 2020, 2019 and 2018, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income. Research and Development Costs Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years. Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material. Incentive Compensation Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved. Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized. The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense. Earnings Per Share Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect. Stock-Based Compensation The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.
Business Description and Basis of Presentation [Text Block]	Description of Business Luminex Corporation, the “Company” or “Luminex,” develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences industries, including diagnostics, pharmaceutical and research. These industries depend on a broad range of tests, called assays, to perform diagnostic testing and conduct life science research. The Company established a position in several segments of the life sciences industries by developing and delivering products that satisfy a variety of customer needs in specific market segments, including multiplexing, accuracy, precision, sensitivity, specificity, reduction of labor and ability to test for proteins and nucleic acids. These needs are addressed by the Company’s proprietary technologies. Multiplexing, the foundation of the Company, allows the end user in a laboratory to generate multiple laboratory results from a single sample with a single assay. This is important because the Company’s end user customers, which include laboratory professionals performing discovery and research and clinical laboratories performing tests on patients as ordered by physicians and other laboratories, have a fundamental need to perform high quality testing as efficiently as possible. Until the availability of multiplexing technology, the laboratory professional had to perform one assay at a time in a sequential manner, and if additional testing was required on a sample, a second assay would be performed to generate the second result, and so on until all the necessary tests were performed. The Company primarily serves the life sciences industries by marketing products, including our specific testing equipment and assays, to various types of testing laboratories. As of December 31, 2020, the Company had 82 strategic partners, 54 of which have released commercialized reagent-based products utilizing the Company’s technology. Luminex and these partners have sold approximately 17,900 xMAP-based instruments in laboratories worldwide as of December 31, 2020, some of which may be retired or otherwise not in use. The Company’s remaining partners are in various stages of development and commercialization of products incorporating the Company’s technology.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated upon consolidation.
Estimates and Assumptions	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts and results could differ from those estimates, and such differences could be material to the financial statements.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents consist of cash deposits and highly liquid investments with original maturities of three months or less when purchased.
Investments	Investments    The Company determines the appropriate classification of its investments in equity securities at the time of purchase and reevaluates such determinations at each balance sheet date.
Fair Value Measurements	Fair Value of Financial Instruments The fair values of financial instruments are determined by obtaining non-binding market prices from the Company’s third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets or inputs other than quoted prices that are observable either directly or indirectly in determining fair value. The Company’s financial instruments include cash and cash equivalents, short-term investments, accounts receivable, equity-method investments, long-term investments, accounts payable and accrued liabilities. The fair values of these financial instruments were not materially different from their carrying or contract values at December 31, 2020 and 2019. See Note 6 for further details concerning fair value measurements.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist of short-term and long-term investments and trade receivables. The Company provides credit, in the normal course of business, to a number of its customers geographically dispersed primarily throughout the U.S. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses, but the Company does not require collateral.
Inventory, Policy [Policy Text Block]	Inventories    Inventories, consisting primarily of raw materials and purchased components, are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. As a developer and manufacturer of high technology medical equipment, the Company may be exposed to a number of economic and industry factors that could result in portions of inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes in the Company’s markets, ability to meet changing customer requirements, competitive pressures on products and prices, and reliability and replacement of and the availability of key components from suppliers. The Company’s policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon the Company’s assumptions about future demand for products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product expiration or end of life dates, estimated current and future market values and new product introductions. Assumptions used in determining the Company’s estimates of future product demand may prove to be incorrect, in which case the provision required for excess and obsolete inventory would have to be adjusted. If inventory is determined to be above the lower of cost or net realizable value, excess or obsolete, the Company would be required to record impairment charges within cost of goods sold at the time of such determination. Although considerable effort is made to ensure the accuracy of forecasts of future product demand, any significant unanticipated changes in demand or expected usage could have a significant negative impact on the value of inventory and the Company’s operating results. When recorded, reserves are intended to reduce the carrying value of inventory to its net realizable value.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are carried at cost less accumulated amounts for amortization and depreciation. Property and equipment are typically amortized or depreciated on a straight-line basis over the useful lives of the assets, which typically range from two to seven years. Leasehold improvements and equipment under capital leases are amortized on a straight-line basis over the shorter of the remaining term of the lease or the estimated useful life of the improvements and equipment. The Company classifies the carrying value of Luminex’s xMAP, ARIES and VERIGENE Systems placed within the reagent rental program and the instruments on loan to customers in property and equipment as “Assets on loan/rental.” Leases
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and Other Intangible Assets Goodwill represents the excess of the cost over the fair value of the assets of the acquired business. In accordance with Accounting Standards Codification (ASC) 350 “Goodwill and Other” (ASC 350), goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise, tested at our sole reporting unit level. Events or circumstances that could trigger an impairment test include, but are not limited to, a significant adverse change in the business climate, significant changes in our use of the acquired assets, significant negative industry or economic trends, significant under-performance relative to operating performance indicators and significant changes in competition. The Company determined that no triggering events occurred during the year ended December 31, 2020. In 2020 and 2019, the Company estimated the fair value of the reporting unit using a fair-value-based approach based on the market capitalization. Determining the fair value of goodwill is subjective in nature and often involves the use of estimates and assumptions including, without limitation, use of estimates of future prices and volumes for the Company’s products, capital needs, economic trends and other factors which are inherently difficult to forecast. The Company’s annual test did not result in an impairment charge in 2020, as the estimated fair value of the reporting unit continued to exceed the carrying value by a significant enough amount such that any reasonably likely change in the assumptions used in the analysis would not cause the carrying value to exceed the estimated fair value for the reporting unit. No goodwill impairments were recorded in 2020, 2019 or 2018. Intangible assets are amortized on a straight-line basis over their respective estimated useful lives ranging from 9 to 15 years. Any in-process research and development will be an indefinite-lived intangible asset until completion or abandonment, at which point it will be accounted for as a finite-lived intangible asset or written off if abandoned.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets and is recorded in the period in which the determination was made.
Revenue Recognition, Policy [Policy Text Block]	Performance Obligations: Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily support and maintenance services on the Company’s systems. The Company recognizes revenue when the customer obtains control of promised products or services, in an amount that reflects the consideration which the Company expects to receive in exchange for these products or services. To determine revenue recognition for arrangements, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or service underlying each performance obligation and recognizes as revenue when such performance obligation is satisfied. Revenue recognition typically occurs upon shipment or delivery to the customer depending upon the shipping terms. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost. Our customers do not typically have any contractual rights of return outside of our warranty provisions. The Company has allowed few returns to date and believes that returns of its products will be minimal in the future. Royalties: For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied. Royalty payments are typically received when our strategic partners report the end-user sales to the Company. Reagent Rentals: The Company provides systems and certain other hardware to customers through reagent rental agreements, under which the customers commit to purchasing minimum quantities of assays at a stated price over a defined contract term, which is normally two to three years. Instead of rental payments, the Company recovers the cost of providing the system and other hardware in the amount charged for assays. Revenue is recognized over the defined contract term as assays are shipped. The depreciation costs associated with the system and other hardware are charged to cost of sales on a straight-line basis over the estimated life of the system. The costs to maintain these instruments in the field are charged to cost of sales as incurred. Under the guidance, the Company reclassified the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements from assay revenue to system revenue. Warranties: The Company provides a limited, assurance-type warranty, typically for twelve months from installation for the systems sold to end customers and fifteen months for the systems sold to partners. The Company accrues for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. While the Company believes that adequate reserve has been made in the consolidated financial statements for product warranties, should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Warranty expenses are evaluated and adjusted periodically. License Revenues: The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third parties. These licenses are typically not distinct, as the customer cannot benefit from the license on its own, and do not have significant standalone functionality, but represent single performance obligations together with the sales of our consumables, systems and assays. The terms of these arrangements typically include payment to the Company of non-refundable, up-front license fees and can extend up to twenty years. Each of these payments results in license revenues which are recognized ratably over time and are included in other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. Deferred revenues related to these out-licensing agreements are shown in contract liabilities in Note 18, “Revenue Recognition”. Service Agreements: Revenue from extended service agreements is deferred when payment is received in advance of the performance obligation being satisfied or completed. Luminex provides an integrated service of maintenance and related activities for equipment sold to customers, where the nature of the overall promise is to provide a stand-ready service. As such, the performance obligation is recognized as a series of distinct service periods and the service revenue is recognized ratably over the term of each agreement. The extended service agreements typically range from one to four years and payment is typically received up-front. Reserves for Variable Consideration : Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts and any other allowances that are offered within contracts between the Company and its customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual requirements, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of each contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period when such variances become known.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Receivables and Allowance for Doubtful Accounts: We recognize receivables when we have an unconditional right to payment, which represents the amount we expect to collect in a transaction and is most often equal to the transaction price in the contract. The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, which is based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together, as similar risk characteristics exist between them. On the rare occasion that interest is charged on trade receivables, it is recognized when received and there are no related fees and costs. Receivable balances are written off to the allowance for doubtful accounts when, in the judgment of management, they are considered uncollectible. The Company's credit losses have historically been within the Company’s expectations, but there can be no assurance that the Company will continue to experience the same level of credit losses that it has in the past. A significant change in the liquidity or financial position of any one of the Company’s significant customers, or a deterioration in the economic environment in general, could have a material adverse impact on the collectability of the Company’s accounts receivable and its future operating results, including a reduction in future revenues and additional allowances for doubtful accounts.
Cost of Sales, Policy [Policy Text Block]	Product-Related Expenses The Company provides for the estimated cost of initial product warranties at the time revenue is recognized. While the Company engages in product quality programs and processes, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage or service delivery costs differ from the Company’s estimates, revisions to the estimated warranty liability would be required. Shipping and handling costs associated with product sales are included in cost of sales. Advertising costs are charged to operations as incurred. The Company does not have any direct-response advertising. Advertising expenses, which include trade shows and conventions, were approximately $1.4 million, $3.5 million and $2.8 million for 2020, 2019 and 2018, respectively, and were included in selling, general and administrative expense in the Consolidated Statements of Comprehensive Income.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are expensed in the period incurred. Nonrefundable advance payments for research and development activities for materials, equipment, facilities and purchased intangible assets that have an alternative future use are deferred and capitalized. In addition, the Company capitalizes certain internally developed products used for evaluation during development projects that also have alternative future uses. These internally developed assets are generally depreciated on a straight-line basis over the useful life of the assets, which range from one to five years.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830, “Foreign Currency Matters.” The reporting currency for the Company is the U.S. dollar. With the exception of its Canadian subsidiary, whose functional currency is the U.S. dollar, the functional currency of the Company’s foreign subsidiaries is their local currency. Accordingly, assets and liabilities of these subsidiaries are translated at the exchange rate in effect at each balance sheet date. Before translation, the Company re-measures foreign currency denominated assets and liabilities, including inter-company accounts receivable and payable, into the functional currency of the respective entity, resulting in unrealized gains or losses recorded in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income. Revenues and expenses are translated using average exchange rates during the respective period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are included in selling, general and administrative expenses in the Consolidated Statement of Comprehensive Income and to date have not been material.
Compensation Related Costs, Policy [Policy Text Block]	Incentive Compensation Management incentive plans are tied to various financial and non-financial performance metrics. Bonus accruals made throughout the year related to the various incentive plans are based on management’s best estimate of the achievement of the specific metrics. Adjustments to the accruals are made on a quarterly basis as forecasts of performance are updated. At year-end, the accruals are adjusted to reflect the actual results achieved.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that those assets will be realized. The Company accounts for uncertain tax positions in accordance with ASC 740, “Income Taxes”, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company’s financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.
Earnings Per Share	Earnings Per Share Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common shares and potential common shares from outstanding stock options, restricted stock units (RSUs) and contingently issuable shares resulting from an award subject to performance or market conditions determined by applying the treasury stock method. In periods with a net loss, potentially dilutive securities composed of incremental common shares issuable upon the exercise of stock options and warrants, and common shares issuable on conversion of preferred stock, would be excluded from historical diluted loss per share because of their anti-dilutive effect.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based employee compensation plans under the fair value recognition and measurement provisions of ASC 718 “Stock Compensation” (ASC 718). ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options, restricted stock units and shares issued under the Company’s employee stock purchase plan. Pursuant to ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period.

INVESTMENTS (Tables)

INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Other Investments Not Readily Marketable [Table Text Block]	2020 2019 Purchased technology rights (net of accumulated amortization of $8,872 and $8,300 in 2020 and 2019, respectively) $ 5,454 $ 6,027 Minority interest and equity method investments 9,909 11,501 Other 1,137 1,594 $ 16,500 $ 19,122
Marketable Securities [Table Text Block]	Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money Market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 707 $ — $ — $ 707	Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money Market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 707 $ — $ — $ 707
Cost-method Investments, Description [Text Block]	In August 2018, the Company exercised its purchase option on a second private company and acquired 100% of its capital stock in a non-cash transaction involving (i) a prior investment of $2.0 million being applied to the purchase option, (ii) the forgiveness and application of a $2.4 million note and related interest receivable to the purchase option and (iii) a tax impact of $0.1 million. This acquisition was accounted for as an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, a next generation technology. The Company recorded the $4.3 million asset acquisition as a defensive, in-process research and development (IP R&D) intangible asset. There were no gains or losses recognized as part of this transaction.    The Company owned a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We were informed that this private company will be dissolving and ceasing operations in the first quarter of 2020. We received cash representing the majority of our investment in the fourth quarter of 2019 and recorded an impairment of $205,000 in Other income, net in the Consolidated Statements of Comprehensive Income during 2019 based upon these circumstances. We received the final cash payment for the remainder of this minority interest in the first quarter of 2020, recorded in cash flows from investing activities in the Consolidated Statements of Cash Flows.    These minority interest investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the $205,000 impairment in 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments.
Investments and Other Noncurrent Assets [Text Block]		NOTE 2 — INVESTMENTS AND OTHER ASSETS Marketable Securities The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. Available-for-sale securities consisted of the following as of December 31, 2020 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money Market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 707 $ — $ — $ 707 Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money Market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 707 $ — $ — $ 707 There were no proceeds from the sales of available-for-sale securities for the years ended December 31, 2020 and December 31, 2019.
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Marketable Securities The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. Available-for-sale securities consisted of the following as of December 31, 2020 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money Market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 707 $ — $ — $ 707 Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money Market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 707 $ — $ — $ 707 There were no proceeds from the sales of available-for-sale securities for the years ended December 31, 2020 and December 31, 2019.

ACCOUNTS RECEIVABLE (Tables)

ACCOUNTS RECEIVABLE (Tables)	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	2020 2019 Accounts receivable $ 68,629 $ 56,956 Less: Allowance for doubtful accounts (1,666) (1,141) $ 66,963 $ 55,815
Allowance for Credit Losses on Financing Receivables [Table Text Block]	Balance at December 31, 2017 $ 1,345 Net increases charged to costs and expenses (437) Write-offs of uncollectible accounts (65) Balance at December 31, 2018 $ 843 Net recoveries charged to costs and expenses 400 Write-offs of uncollectible accounts (102) Balance at December 31, 2019 1,141 Net recoveries charged to costs and expenses 546 Write-offs of uncollectible accounts (21) Balance at December 31, 2020 1,666

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Components of Inventories	2020 2019 Parts and supplies $ 86,380 $ 45,459 Work-in-progress 18,858 15,532 Finished goods 17,896 16,093 $ 123,134 $ 77,084

FAIR VALUE (Tables)

FAIR VALUE (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]	Fair Value Measurements as of December 31, 2020 Using Level 1 Level 2 Level 3 Total Assets: Money Market funds $ 707 $ — $ — $ 707 Equity investment $ — $ — $ 9,909 $ 9,909

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	2020 2019 Laboratory equipment $ 70,189 $ 60,486 Leasehold improvements 45,784 43,471 Computer equipment 4,034 3,916 Purchased software 22,981 22,621 Furniture and fixtures 6,081 5,924 Assets on loan/rental 32,544 28,946 181,613 165,364 Less: Accumulated depreciation (117,467) (99,849) $ 64,146 $ 65,515

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2019 Balance as of December 31, 2018 $ 98,469 $ 23,819 $ 10,655 $ 24,013 $ 156,956 Flow cytometry acquisition purchase price allocation adjustments (116) (428) 1,154 (4,016) (3,406) Balance as of December 31, 2019 98,353 23,391 11,809 19,997 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2018 (40,501) (9,036) (2,271) — (51,808) Amortization expense (7,784) (2,428) (1,194) — (11,406) Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Net balance as of December 31, 2019 $ 50,068 $ 11,927 $ 8,344 $ 19,997 $ 90,336 Weighted average life (in years) 11 10 10 2020 Balance as of December 31, 2019 $ 98,353 $ 23,391 $ 11,809 $ 19,997 $ 153,550 Completion of IPR&D projects 2,687 (2,687) — Balance as of December 31, 2020 101,040 23,391 11,809 17,310 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Amortization expense (7,919) (2,427) (1,194) — (11,540) Accumulated amortization balance as of December 31, 2020 (56,204) (13,891) (4,659) — (74,754) Net balance as of December 31, 2020 $ 44,836 $ 9,500 $ 7,150 $ 17,310 $ 78,796 Weighted average life (in years) 11 10 10
Estimated Future Amortization Expense Related to Intangible Assets	2020 $ 11,316 2021 10,070 2022 9,721 2023 9,721 2024 8,188 Thereafter 12,470 $ 61,486

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	2020 2019 Compensation and employee benefits $ 33,992 $ 17,011 Dividends payable 4,711 4,104 Income and other taxes 7,058 1,538 Warranty costs 1,849 1,641 Royalties payable 782 1,335 Current operating lease liabilities 5,942 5,053 Convertible notes interest payable 996 — Other 1,035 1,190 $ 56,365 $ 31,872
Schedule of Product Warranty Liability [Table Text Block]	Accrued warranty costs at December 31, 2017 $ 1,308 Warranty services provided (2,159) Accrual for warranty costs 2,752 Accrued warranty costs at December 31, 2018 1,901 Warranty services provided (2,868) Accrual for warranty costs 2,608 Accrued warranty costs at December 31, 2019 1,641 Warranty services provided (2,362) Accrual for warranty costs 2,570 Accrued warranty costs at December 31, 2020 $ 1,849

INCOME TAXES Tables (Tables)

INCOME TAXES Tables (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	2020 2019 2018 Domestic $ (33,631) $ (31,314) $ 7,242 Foreign 62,571 21,812 21,069 Total $ 28,940 $ (9,502) $ 28,311
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2020 2019 2018 Current: Federal $ (7) $ 821 $ (3,318) Foreign 6,689 951 515 State 179 (163) 600 Total current expense (benefit) $ 6,861 $ 1,609 $ (2,203) Deferred: Federal (2,913) (10,179) 6,351 Foreign 8,886 4,597 5,271 State 936 (1,691) 384 Total deferred expense (benefit) 6,909 (7,273) 12,006 Total provision (benefit) for income taxes $ 13,770 $ (5,664) $ 9,803
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2020 2019 2018 Statutory tax rate 21.0 % 21.0 % 21.0 % State taxes, net of federal benefit (3.5) % 9.6 % 3.0 % Permanent items (2.4) % (1.6) % 2.6 % Effect of foreign operations 10.2 % (11.7) % 3.4 % Research and incentive tax credit generated (7.7) % 18.9 % (8.7) % Valuation allowance 9.1 % 0.8 % 0.4 % Income tax reserves 1.0 % 67.3 % 24.7 % Remeasurement U.S. deferreds 0.0 % 0.0 % (0.3) % Transition tax 0.0 % (5.3) % (16.6) % Foreign earnings withholding tax 0.1 % 6.6 % (7.9) % Global intangible low-taxed income 18.6 % (44.4) % 5.7 % Other measurement period Tax Act adjustments 0.0 % 0.0 % 2.6 % Canadian income tax audit 0.0 % 0.0 % 4.8 % Other 1.2 % (1.0) % (0.1) % 47.6 % 60.2 % 34.6 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2020 2019 Deferred tax assets: Accrued liabilities and other $ 7,479 $ 4,577 Net operating loss and credit carryforwards 40,966 52,141 Deferred revenue 2,119 1,023 Operating lease liability 4,060 5,023 Stock compensation and other 7,542 7,791 Bond hedge 12,103 — Gross deferred tax assets 74,269 70,555 Valuation allowance (16,882) (17,906) Total deferred tax assets $ 57,387 $ 52,649 Deferred tax liabilities: Accrued liabilities and other $ (4,230) $ (1,287) Depreciation and amortization (15,710) (18,443) Operating lease right-of-use assets (3,649) (4,550) Equity method investment (279) (667) Convertible debt (12,442) Total deferred tax liabilities (36,310) (24,947) Net deferred tax assets $ 21,077 $ 27,702
Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]	2020 2019 Balance at beginning of year $ 3,423 $ 9,721 Additions based on tax positions related to the current year 311 342 Additions for tax positions of prior years — 398 Reductions for tax positions of prior years (30) (7,038) Balance at end of year $ 3,704 $ 3,423

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Basic and Diluted Earnings Per Share	Year Ended December 31, 2020 2019 2018 Basic: Net income (loss) $ 15,170 $ (3,838) $ 18,508 Less: allocation to participating securities (297) 65 (312) Net income (loss) attributable to common stockholders $ 14,873 $ (3,773) $ 18,196 Weighted average common stock outstanding 45,102 44,148 43,727 Net income (loss) per share attributable to common stockholders $ 0.33 $ (0.09) $ 0.42 Diluted: Net income (loss) $ 15,170 $ (3,838) $ 18,508 Less: allocation to participating securities (298) 63 (311) Net income (loss) attributable to common stockholders $ 14,872 $ (3,775) $ 18,197 Weighted average common stock outstanding 45,102 44,148 43,727 Effect of dilutive securities: stock options and awards 718 — 564 Weighted-average shares used in computing net income (loss) per share 45,820 44,148 44,291 Net income (loss) per share attributable to common stockholders $ 0.32 $ (0.09) $ 0.41

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 2019 2018 Dividend yield 1.5 % 0.9 % 1.2 % Expected volatility 0.3 0.4 0.4 Risk-free rate of return 0.9 % 2.6 % 2.7 % Expected life of a 10 year contractual term option 7 years 7 years 7 years Expected life of a 7 year contractual term option 4.75 years 4.88 years 4.88 years Weighted average fair value at grant date $ 6.17 $ 7.69 $ 8.23
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	2020 2019 2018 Assumptions: Risk-free interest rates 0.18 % 2.55 % 2.1 % Expected life 0.5 years 0.5 years 0.5 years Expected volatility 0.3471 0.35 0.44 Dividend yield 1.454 % 0.942 % 1.2 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Operating Leases 2021 $ 7,206 2022 5,540 2023 4,507 2024 3,177 2025 945 Thereafter — Total lease payments 21,375 Less: imputed interest (2,067) Lease liabilities at December 31, 2020 $ 19,308

ACCOUNTS RECEIVABLE (Details)

ACCOUNTS RECEIVABLE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Receivables [Abstract]
Accounts Receivable, Gross, Current	$ 68,629	$ 56,956
Allowance for Doubtful Accounts Receivable	(1,666)	(1,141)	$ (843)	$ (1,345)
Allowance for Doubtful Accounts Receivable, Period Increase (Decrease)	(546)	400	(437)
Allowance for Doubtful Accounts Receivable, Write-offs	(21)	(102)	$ (65)
Accounts Receivable, Net, Current	$ 66,963	$ 55,815

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory, Raw Materials and Purchased Parts, Net of Reserves	$ 86,380	$ 45,459
Inventory, Work in Process, Net of Reserves	18,858	15,532
Inventory, Finished Goods, Net of Reserves	17,896	16,093
Inventory, Net	$ 123,134	$ 77,084

FAIR VALUE (Details)

FAIR VALUE (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 707	$ 707
Cost Method Investments, Fair Value Disclosure		22
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	707	707
Cost Method Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Cost Method Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 0	0
Cost Method Investments, Fair Value Disclosure		$ 22

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Gross	$ 181,613	$ 165,364
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(117,467)	(99,849)
Depreciation	18,400	16,500
Property, Plant and Equipment, Net	$ 64,146	$ 65,515

GOODWILL (Details)

GOODWILL (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 118,145	$ 118,145	$ 118,127
Goodwill, Acquired During Period	$ 0	$ 18

INTANGIBLE ASSETS (Detail)

INTANGIBLE ASSETS (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	$ (74,754)	$ (63,214)	$ (51,808)
Indefinite-lived Intangible Assets (Excluding Goodwill)	17,310	19,997	24,013
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	12,470
Finite-Lived Intangible Assets, Amortization Expense, Year Three	9,721
Finite-Lived Intangible Assets, Amortization Expense, Year Two	10,070
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	11,316
Finite-Lived Intangible Assets, Amortization Expense, Year Four	9,721
Finite-Lived Intangible Assets, Amortization Expense, Year Five	8,188
Intangible Assets, Net (Excluding Goodwill)	78,796	90,336
Intangible Assets, Gross (Excluding Goodwill)	153,550	153,550	156,956
Indefinite-lived Intangible Assets, Period Increase (Decrease)		(4,016)
Indefinite-lived Intangible Assets Acquired	(2,687)
Amortization of Intangible Assets	(11,542)	(11,407)	(8,665)
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(56,204)	(48,285)	(40,501)
Finite-Lived Intangible Assets, Gross	101,040	98,353	98,469
Finite-Lived Intangible Assets, Net	$ 44,836	$ 50,068
Finite-Lived Intangible Asset, Useful Life	11 years	11 years
Finite-Lived Intangible Assets, Period Increase (Decrease)		$ (116)
Finite-lived Intangible Assets Acquired	$ 2,687
Amortization of Intangible Assets	(7,919)	(7,784)
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(13,891)	(11,464)	(9,036)
Finite-Lived Intangible Assets, Gross	23,391	23,391	23,819
Finite-Lived Intangible Assets, Net	$ 9,500	$ 11,927
Finite-Lived Intangible Asset, Useful Life	10 years	10 years
Finite-Lived Intangible Assets, Period Increase (Decrease)		$ (428)
Finite-lived Intangible Assets Acquired
Amortization of Intangible Assets	(2,427)	(2,428)
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(4,659)	(3,465)	(2,271)
Finite-Lived Intangible Assets, Gross	11,809	11,809	$ 10,655
Finite-Lived Intangible Assets, Net	$ 7,150	$ 8,344
Finite-Lived Intangible Asset, Useful Life	10 years	10 years
Finite-Lived Intangible Assets, Period Increase (Decrease)		$ 1,154
Finite-lived Intangible Assets Acquired
Amortization of Intangible Assets	$ (1,194)	$ (1,194)

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Employee-related Liabilities, Current	$ 33,992	$ 17,011
Taxes Payable, Current	7,058	1,538
Product Warranty Accrual, Current	1,849	1,641	$ 1,901	$ 1,308
Accrued Royalties, Current	782	1,335
Operating Lease, Liability, Current	5,942	5,053
Standard and Extended Product Warranty Accrual, Decrease for Payments	(2,362)	(2,868)	(2,159)
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued	2,570	2,608	$ 2,752
Dividends Payable, Current	4,711	4,104
Other Accrued Liabilities, Current	1,035	1,190
Accrued Liabilities, Current	56,365	31,872
Interest Payable, Current	$ 996	$ 0

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate	3.00%
Debt Instrument, Convertible, Conversion Price	$ 43.68
Long-term Debt, Gross	$ 260,000
Debt Instrument, Unamortized Discount	(51,352)
Unamortized Debt Issuance Expense	(5,512)
Interest Expense, Debt	$ 11,473	$ 0
Debt Instrument, Convertible, Remaining Discount Amortization Period	4 years 4 months 24 days
Debt Instrument, Convertible, Stock Price Trigger	$ 69.89

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	$ 7,479	$ 4,577
Deferred Tax Assets, Operating Loss Carryforwards	40,966	52,141
Deferred Tax Assets, Deferred Income	2,119	1,023
Deferred Tax Assets, Tax Deferred Expense, Other	4,060	5,023
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other	7,542	7,791
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other	12,103	0
Deferred Tax Assets, Gross	74,269	70,555
Deferred Tax Assets, Valuation Allowance	(16,882)	(17,906)
Deferred Tax Assets, Net of Valuation Allowance	57,387	52,649
Deferred Tax Liabilities, Other	(4,230)	(1,287)
Deferred Tax Liabilities, Deferred Expense	(15,710)	(18,443)
Deferred Tax Liabilities, Leasing Arrangements	(3,649)	(4,550)
Deferred Tax Liabilities, Investment in Noncontrolled Affiliates	(279)	(667)
Deferred Tax Liabilities, Gross	(36,310)	(24,947)
Unrecognized Tax Benefits	3,423	9,721
Unrecognized Tax Benefits	3,704	3,423	$ 9,721
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions	311	342
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions	0	398
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	(30)	(7,038)
Current Federal Tax Expense (Benefit)	(7)	821	(3,318)
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (33,631)	$ (31,314)	$ 7,242
Effective tax rate	47.60%	60.20%	34.60%
U.S. federal statutory tax rate	21.00%	21.00%	21.00%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	(3.50%)	9.60%	3.00%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent	(2.40%)	(1.60%)	2.60%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	10.20%	(11.70%)	3.40%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	(7.70%)	18.90%	(8.70%)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	9.10%	0.80%	0.40%
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent	1.00%	67.30%	24.70%
Effective Income Tax Rate Reconciliation, Deduction, Other, Percent	0.10%	6.60%	(7.90%)
Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent	18.60%	(44.40%)	5.70%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent	0.00%	0.00%	2.60%
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent	0.00%	(5.30%)	(16.60%)
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent	0.00%	0.00%	(0.30%)
Effective Income Tax Rate Reconciliation, Tax Settlement, Foreign, Percent	0.00%	0.00%	4.80%
Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent	1.20%	(1.00%)	(0.10%)
Provision for income taxes	$ 13,770	$ (5,664)	$ 9,803
Income (Loss) from Continuing Operations before Income Taxes, Foreign	62,571	21,812	21,069
Income (Loss) Attributable to Parent, before Tax	28,940	(9,502)	28,311
Current Foreign Tax Expense (Benefit)	6,689	951	515
Current State and Local Tax Expense (Benefit)	179	(163)	600
Current Income Tax Expense (Benefit)	6,861	1,609	(2,203)
Deferred Federal Income Tax Expense (Benefit)	(2,913)	(10,179)	6,351
Deferred Foreign Income Tax Expense (Benefit)	8,886	4,597	5,271
Deferred State and Local Income Tax Expense (Benefit)	936	(1,691)	384
Deferred Income Tax Expense (Benefit)	6,909	(7,273)	$ 12,006
Deferred Tax Assets, Net	$ 21,077	$ 27,702

EARNINGS PER SHARE Details (Det

EARNINGS PER SHARE Details (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic									$ (297)	$ 65	$ (312)
Net Income (Loss) Available to Common Stockholders, Basic									$ 14,873	$ (3,773)	$ 18,196
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									1,620,252	1,271,248	619,113
Net Income (Loss) Available to Common Stockholders, Diluted									$ 14,872	$ (3,775)	$ 18,197
Weighted Average Number of Shares Outstanding, Basic									45,102,000	44,148,000	43,727,000
Earnings Per Share, Basic	$ 0.01	$ 0.04	$ 0.27	$ 0.01	$ 0.08	$ (0.12)	$ (0.11)	$ 0.07	$ 0.33	$ (0.09)	$ 0.42
Net Income (Loss) Attributable to Parent	$ 239	$ 1,767	$ 12,510	$ 654	$ 3,383	$ (5,250)	$ (4,931)	$ 2,960	$ 15,170	$ (3,838)	$ 18,508
Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted									$ (298)	$ 63	$ (311)
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements									718,000	0	564,000
Weighted Average Number of Shares Outstanding, Diluted									45,820,000	44,148,000	44,291,000
Earnings Per Share, Diluted	$ 0.01	$ 0.04	$ 0.27	$ 0.01	$ 0.07	$ (0.12)	$ (0.11)	$ 0.07	$ 0.32	$ (0.09)	$ 0.41

STOCKHOLDERS' EQUITY Details (D

STOCKHOLDERS' EQUITY Details (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Document Period End Date	Dec. 31, 2020
Common Stock, Capital Shares Reserved for Future Issuance	6,808,668	8,349,808
Allocated Share-based Compensation Expense	$ 9,200,000	$ 8,200,000	$ 6,200,000
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	0
Proceeds from Stock Options Exercised	18,000,000	1,700,000	2,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	16,200,000	400,000	1,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	10,500,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	18,700,000
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$ 19,500
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%
Defined Contribution Plan, Administrative Expense	$ 5,400,000	$ 5,100,000	$ 4,000,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans	758,700	631,553	518,111
Stock Issued During Period, Value, Employee Stock Ownership Plan	$ 700,000	$ 600,000	$ 500,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date	15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	1.50%	0.90%	1.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	30.00%	40.00%	40.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.90%	2.60%	2.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	7 years	7 years	7 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 9 months	4 years 10 months 17 days	4 years 10 months 17 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 6.17	$ 7.69	$ 8.23
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,400,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	570,000	522,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	1 year 1 month 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	100,000	120,498	95,127
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 23.09	$ 21.01	$ 21.98
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 31.65	$ 24.43	$ 26.39
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(45,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(7,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	0 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 9,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 7,300,000	$ 6,000,000	$ 6,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 2 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested	$ 13,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	1 year 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 13,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	563,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	403,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	893,000	810,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 22.98	$ 22.28
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	416,000	413,967	387,436
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 23.05	$ 20.04	$ 20.33
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	31.65	$ 24.43	$ 29.33
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 23.26
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(295,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 21.49
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(38,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 22.65
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 10,600,000	$ 11,900,000	$ 12,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 6 months 25 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 6,248,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,753,000	3,793,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 21.25	$ 20.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	4 years 5 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 7,633,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,508,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 23.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(998,000)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 18.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	(550,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 24.43
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	1.454%	0.942%	1.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	34.71%	35.00%	44.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.18%	2.55%	2.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 months	6 months	6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	4 years 5 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$ 7,623,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	3,687,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 21.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,519,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 19.12

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	3 years 6 months 7 days	4 years 4 months 9 days
Lease, Cost	$ 9,792	$ 9,434	$ 7,032
Purchase Obligation	68,100
Recorded Unconditional Purchase Obligation	500
Operating Leases, Future Minimum Payments Due, Next Twelve Months	7,206
Operating Leases, Future Minimum Payments, Due in Two Years	5,540
Operating Leases, Future Minimum Payments, Due in Three Years	4,507
Operating Leases, Future Minimum Payments, Due in Four Years	3,177
Operating Leases, Future Minimum Payments, Due in Five Years	945
Operating Leases, Future Minimum Payments, Due Thereafter	0
Operating Leases, Future Minimum Payments Due	$ 21,375
Operating Lease, Weighted Average Discount Rate, Percent	5.75%	5.75%
Unrecorded Unconditional Purchase Obligation, Imputed Interest	$ (2,067)